# Botulinum Toxin A Injection of the Obturator Internus Muscle for Chronic Perineal Pain

Noor M. Gajraj

**Abstract:** Chronic perineal pain is often a difficult condition to manage. Current treatments include pudendal nerve injections and pudendal nerve release surgery. The obturator internus muscle has a close relationship to the pudendal nerve and might be a potential target for therapeutic intervention. **Perspective:** A case is presented of refractory perineal pain that was successfully treated by injecting the obturator internus muscle with botulinum toxin A.

© 2005 by the American Pain Society

Key words: Chronic pain, perineal pain, obturator internus, botulinum toxin.

he cause of chronic perineal pain is often difficult to identify and the syndrome difficult to treat. 1,39 Musculoskeletal dysfunction might contribute to the signs and symptoms of chronic pelvic pain.<sup>7,57</sup> Although the obturator internus muscle has been identified as a possible pain generator, 18,32,48,60 little has been written about this muscle as a possible target for therapeutic intervention. The fascia of the obturator internus muscle contributes to the formation of the pudendal canal and when thickened might become a possible entrapment site.<sup>47</sup> Injections into the muscle, adjacent to the canal, might have beneficial effects because of actions on both the muscle and the nerve in terms of decreasing compression and modulation of neurotransmitters.<sup>25</sup> Botulinum toxin has been used successfully in the treatment of chronic pain. 10,13,19,20,33,43,49 A case is reported indicating that injection of the obturator internus muscle with botulinum toxin might be a therapeutic option for patients with chronic perineal pain. This case report received institutional review board approval, and the subject of the case report gave signed consent for participation.

# Anatomy of the Pudendal Nerve and Obturator Internus Muscle

Arising from the sacral plexus (S2, 3, 4), the pudendal nerve is a sensory and motor nerve to the peri-

Received June 28, 2004; Revised January 3, 2005; Accepted January 3, 2005

From the Center for Pain Management, Baylor University Medical Center, Frisco, Texas.

Address reprint requests to Noor M. Gajraj, MD, Baylor Center for Pain Management, 5575 Warren Parkway, POB1, Suite 220, Frisco, TX 75034. E-mail: noorgajraj@aol.com

1526-5900/\$30.00


© 2005 by the American Pain Society doi:10.1016/j.jpain.2005.01.353

neum.<sup>51,54</sup> The pudendal nerve enters the gluteal region through the lower part of the greater sciatic foramen below the piriformis muscle. It hooks around the sacrospinous ligament near its attachment to the ischial spine; the pudendal nerve reenters the pelvis through the lesser sciatic foramen and through the pudendal (Alcock's) canal that is formed by the obturator fascia on the lateral wall of the ischioanal fossa (Fig 1). Within the pudendal canal, the pudendal nerve divides into 2 terminal branches, the perineal nerve and the dorsal nerve of the penis or clitoris.

The pudendal canal is a fascial tunnel on the medial aspect of the obturator internus muscle. The obturator internus muscle originates within the pelvis on the obturator membrane, a membrane that closes all but the superior border of the obturator foramen, and on those portions of the pubis and ischium that surround the obturator foramen. It is a lateral rotator of the thigh. Although broad in origin, the muscle tapers to a narrow tendon that passes through the lesser sciatic foramen and rides over the ischial body (over a bursa) just superior to the ischial tuberosity to attach on the medial aspect of the greater trochanter of the femur.

### **Case Report**

A 64-year-old woman complained of right-sided pelvic pain affecting the upper leg, vagina, and rectum. The pain was rated at a level of 4 to 8 out of 10 on a visual analogue scale and had been present for 4 years. The pain was aggravated by sitting. Previous diagnoses made included lumbosacral radiculopathy, post-laminectomy syndrome, pudendal nerve entrapment, sacroiliac joint dysfunction, and piriformis syndrome. The patient had received numerous medications and injection therapies in the past including pudendal nerve injections with local anesthetic and steroid, sacroiliac joint injections, and



**Figure 1.** Anatomy of the obturator internus muscle and pudendal nerve.

piriformis muscle injections. Other previous therapies included physical therapy and water aerobics. The patient also had a pudendal nerve release procedure in France 2 years previously, but with only partial relief. Medications being taken at the time of the office visit included methadone 20 mg twice a day, zonegran 200 mg twice a day, Zoloft 50 mg once daily, valium 5 mg at night, and zanaflex 12 mg at night. Physical examination showed a distressed woman, uncomfortable while sitting, but there were no focal neurologic signs. A vaginal examination was not performed at that time but had been performed by a previous physician and showed tenderness at the right anterior and right posterior lateral regions.

The patient underwent a right obturator internus muscle injection with bupivacaine 0.25%, which gave 90% relief for 12 hours. The average preprocedural and post-procedural visual analogue scale scores were 7 of 10 and 1 of 10, respectively. After a subsequent botulinun toxin A injection, the patient again reported 90% relief from her pain for more than 3 months. Pain assessments were made before the procedure and then at 1-hour intervals after the procedure by using a 0 to 10 numeric rating scale. There were no adverse effects such as motor weakness or disturbance of bowel or bladder function.

## Fluoroscopically Guided Obturator Internus Muscle Injection Technique


The patient was placed in the prone position. Standard monitors were applied consisting of electrocardiogram, pulse oximetry, and an automated blood pressure device. Sedation was achieved by using increments of intravenous midazolam and fentanyl. Fluoroscopy was used to visualize the obturator foramen. The skin and subcutaneous tissues were anesthetized by using 1% lidocaine. With an aseptic technique and transgluteal approach, a 22-gauge spinal needle was advanced to the lateral border of the obturator foramen, inferior to the ischial spine (Fig 2). Correct needle placement was confirmed by injecting 1 mL of iohexol. For the diagnostic injection 5 mL of 0.25% bupivacaine was injected. For

the second injection 100 units of botulinum A in 3 mL 0.25% bupivacaine was injected on a separate occasion.

#### Discussion

Pudendal nerve entrapment is a recognized cause of chronic perineal pain, <sup>42,46,47,54,63,66</sup> typically presenting as pain in the penis, scrotum, labia, perineum, or anorectal region. Pudendal nerve pathology might also cause urinary incontinence, anal incontinence, and dysorgasmia. Pudendal nerve entrapment is a clinical diagnosis made in patients with the typical history of perineal pain aggravated by sitting, relieved by standing, and absent when recumbent or sitting on a toilet seat. No widely accepted confirmatory test is available, although a neurophysiologic examination might confirm nerve damage.<sup>34</sup>

The pudendal nerve is predisposed to entrapment at the level of the ischial spine and within the pudendal canal.<sup>2,53</sup> At the ischial spine, the nerve can be compressed between the sacrotuberous and sacrospinous ligaments. At the pudendal canal, the pudendal nerve can be compressed by the falciform process of the sacrotuberous ligament. The fascia on the obturator internus contributes to the formation of the pudendal canal. If thickened, the obturator fascia also might act as an entrapment site.<sup>47</sup> Treatments for pudendal nerve entrapment include local anesthetic and steroid injections, neurolysis, and surgical decompression. 11,24,35,36,47,64 The analgesic effects of botulinum toxin have been reported in patients with cervical dystonia and spastic disorders. 12,30,61,65 More patients reported improvement in pain than dystonia, raising the possibility that pain relief might not be solely the result of reduced muscular contractions. 65 Botulinum toxin has been used successfully in pain management for a number of conditions including headache, 17,41,50,52,59,62 temporomandibular disorders, 16



**Figure 2.** Fluoroscopic view of right obturator internus muscle injection.

neck pain, 21,68 low back pain, 14,15,26,44 piriformis syndrome, 31 nonrelaxing puborectalis syndrome, 55 spasm of the levator ani muscles, 28 and vulvodynia. 19 Botulinum toxin not only inhibits acetylcholine release but also the release of pain neurotransmitters such as glutamate, substance P, calcitonin gene-related peptide, and histamine. 6,8,56,9,4,25,29,67 Reduced neurotransmitter release might prevent local sensitization of nociceptors and thus reduce the perception of pain. Botulinum toxin might also alter impulse transmission within the dorsal horn pathways responsible for hyperalgesic mediation.3 Other proposed mechanisms of action include changes in the sensitivity and response patterns of muscle nociceptors, diminished activity in the gamma-motor neurons with consequent changes in muscle spindle afferents, alterations in cholinergic control of vascular and autonomic functions, and direct noncholinergic effects on pain afferents.<sup>5</sup> The duration of action of botulinum toxin correlates with neural sprouting and reinnervation of the muscle, which restores function in 1 to 4 months.<sup>23</sup> Adverse events from botulinum toxin therapy are not generally serious and might include localized pain, tenderness,

and bruising at the injection site, a flu-like syndrome, <sup>27</sup> weakness of adjacent musculature, dry mouth, dysphagia, and formation of neutralizing antibodies. <sup>37,38</sup> Although botulinum toxin is not recommended as a first-line therapy for pain management, <sup>58</sup> it can be very useful in refractory cases. <sup>45</sup> Botulinum toxin is usually reconstituted by mixing the contents of a vial with normal saline, although it is also common practice to use local anesthetic as a diluent. <sup>43</sup> In the case reported, the pain relief obtained by the botulinum toxin injection might have resulted in part from the bupivacaine, although this effect would be expected to last only hours rather than months. Injection of botulinum toxin into the obturator internus muscle has not been previously described.

In conclusion, obtutator internus muscle injections might be a therapeutic option for patients with chronic perineal pain whose other treatments have failed. The precise mechanism of action and the relative actions on the muscle and pudendal nerve remain to be elucidated. Evidence for efficacy from a single case report clearly has limitations, <sup>22,40</sup> and so future randomized controlled studies are required.

#### References

- 1. Clinical Management Guidelines for Obstetrician-Gynecologists: Number 51, March 2004: Chronic Pelvic Pain. Obstet Gynecol 103:589-605, 2004
- 2. Amarenco G, Lanoe Y, Ghnassia RT, Goudal H, Perrigot M: Alcock's canal syndrome and perineal neuralgia. Rev Neurol (Paris) 144:523-526, 1988
- 3. Andersen OK, Gracely RH: Facilitation of the human nociceptive reflex by stimulation of A beta-fibres in a secondary hyperalgesic area sustained by nociceptive input from the primary hyperalgesic area. Acta Physiol Scand 155:87-97, 1995
- 4. Aoki KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43:S9-S15, 2003
- 5. Arezzo JC: Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain 18:S125-S132, 2002
- 6. Ashton AC, Dolly JO: Characterization of the inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes. J Neurochem 50:808-816, 1988
- 7. Baker PK: Musculoskeletal origins of chronic pelvic pain: Diagnosis and treatment. Obstet Gynecol Clin North Am 20: 719-742, 1993
- 8. Bigalke H, Heller I, Bizzini B: Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord. Naunyn Schmiedebergs Arch Pharmacol 316:244-251, 1981
- 9. Borodic G, Acquadro M, Johnson E: Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs 10:1531-1544, 2001

- 10. Borodic GE, Acquadro MA, Johnson EA: The use of botulinum toxin for the treatment of chronic facial pain. J Pain 3:21-27, 2002
- 11. Calvillo O, Skaribas IM, Rockett C: Computed tomography-guided pudendal nerve block. A new diagnostic approach to long-term anoperineal pain: A report of two cases. Reg Anesth Pain Med 25:420-423, 2000
- 12. Chalkiadaki A, Rohr UP, Hefter H: Early pain reduction in the treatment of spasticity after a single injection of botulinum A toxin. Dtsch Med Wochenschr 126:1361-1364, 2001
- 13. Cheshire WP, Abashian SW, Mann JD: Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59:65-69, 1994
- 14. Difazio D, Jabbari B: A focused review of the use of botulinum toxins for low back pain. Clin J Pain 18:S155-S162, 2002
- 15. Foster L, Clapp L, Erickson M, Jabarri B: Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology 56:1290-1293, 2001
- 16. Freund B, Schwartz M, Symington JM: Botulinum toxin: New treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 38:466-471, 2000
- 17. Gobel H, Heinze A, Heinze-Kuhn K, Austermann K: Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 91:195-199, 2001
- 18. Guis-Sabatier S, Pieri-Balandraud N, Garnier-Soumet P, Coste J, Roux H, Mattei JP: Pubic pain in athletes: A case due to an abscess in the obturator muscle. Rev Rhum Engl Ed 66:58-60, 1999
- 19. Gunter J, Brewer A, Tawfik O: Botulinum toxin a for vulvodynia: A case report. J Pain 5:238-240, 2004
- 20. Guyer BM: Mechanism of botulinum toxin in the relief of chronic pain. Curr Rev Pain 3:427-431, 1999

Chronic Perineal Pain

- 21. Herskowitz A, Herskowitz B: Treatment of neck and shoulder pain with botulinum neurotoxins. Pain Practice 4:S27-S37, 2004
- 22. Hodgson M: N-of-one clinical trials: The practice of environmental and occupational medicine. J Occup Med 35: 375-380, 1993
- 23. Holds JB, Alderson K, Fogg SG, Anderson RL: Motor nerve sprouting in human orbicularis muscle after botulinum A injection. Invest Ophthalmol Vis Sci 31:964-967, 1990
- 24. Hough DM, Wittenberg KH, Pawlina W, Maus TP, King BF, Vrtiska TJ, Farrell MA, Antolak SJ: Chronic perineal pain caused by pudendal nerve entrapment: Anatomy and CT-guided perineural injection technique. Am J Roentgenol 181:561-567, 2003
- 25. Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 44:106-109, 2000
- 26. Jabbari B, Ney J: Treatment of low back pain with botulinum neurotoxins. Pain Practice 4:S47-S53, 2004
- 27. Jankovic J, Brin MF: Therapeutic uses of botulinum toxin. N Engl J Med 324:1186-1194, 1991
- 28. Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG: Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol 44:46-50, 2004
- 29. Johnson EA: Clostridial toxins as therapeutic agents: Benefits of nature's most toxic proteins. Ann Rev Microbiol 53:551-575, 1999
- 30. Kelm S, Gerats G, Chalkiadaki A, Hefter H: Reduction of pain and muscle spasms by botulinum toxin A. Nervenarzt 72:302-306, 2001
- 31. Lang AM: Botulinum toxin type B in piriformis syndrome. Am J Phys Med Rehabil 83:198-202, 2004
- 32. Leigh RE: Obturator internus spasm as a cause of pelvic and sciatic distress. Lancet 72:286-287, 1952
- 33. Lew MF: Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 18:S142-S146, 2002
- 34. Loening-Baucke V, Read NW, Yamada T, Barker AT: Evaluation of the motor and sensory components of the pudendal nerve. Clin Neurophysiol 93:35-41,1994
- 35. Mauillon J, Thoumas D, Leroi AM, Freger P, Michot F, Denis P: Results of pudendal nerve neurolysis-transposition in twelve patients suffering from pudendal neuralgia. Dis Colon Rectum 42:186-192, 1999
- 36. McDonald JS, Spigos DG: Computed tomographyguided pudendal block for treatment of pelvic pain due to pudendal neuropathy. Obstet Gynecol 95:306-309, 2000
- 37. Naumann M, Jankovic J: Safety of botulinum toxin type A: A systematic review and meta-analysis. Curr Med Res Opin 20:981-990, 2004
- 38. Naumann M, Yakovleff A, Durif F: A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol 249:57-63, 2002
- 39. Neill ME, Swash M: Chronic perianal pain: An unsolved problem. J R Soc Med 75:96-101, 1982

- 40. O'Brien PC: The use and misuse of N-of-one studies. Int J Oral Maxillofac Implants 12:293, 1997
- 41. Padberg M, de Bruijn SF, de Haan RJ, Tavey DLJ: Treatment of chronic tension-type headache with botulinum toxin: A double-blind, placebo-controlled clinical trial. Cephalalgia 24:675-680, 2004
- 42. Pisani R, Stubinski R, Datti RA: Entrapment neuropathy of the internal pudendal nerve: Report of two cases. Scand J Urol Nephrol 31:407-410, 1997
- 43. Porta M: A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 85:101-105, 2000
- 44. Raj PP: Botulinum neurotoxin in chronic pain management. Pain Practice 4:S68-S72, 2004
- 45. Raj PP: Treatment algorithm overview: BoNT therapy for pain. Pain Practice 4:S54-S67, 2004
- 46. Ramsden CE, McDaniel MC, Harmon RL, Renney KM: Pudendal nerve entrapment as source of intractable perineal pain. Am J Phys Med Rehabil 82:479-484, 2003
- 47. Robert R, Prat-Pradal D, Labat JJ, Bensignor M, Raoul S, Rebai R, Leborgne L: Anatomic basis of chronic perineal pain: Role of the pudendal nerve. Surg Radiol Anat 20:93-98, 1998
- 48. Rohde RS, Ziran BH: Obturator internus tendinitis as a source of chronic hip pain. Orthopedics 26:425-426, 2003
- 49. Royal MA: Botulinum toxins in pain management. Phys Med Rehabil Clin N Am 14:805-820, 2003
- 50. Royal MA: The use of botulinum toxins in the management of pain and headache. Pain Practice 1:215-235, 2001
- 51. Schraffordt SE, Tjandra JJ, Eizenberg N, Dwyer PL: Anatomy of the pudendal nerve and its terminal branches: A cadaver study. ANZ J Surg 74:23-26, 2004
- 52. Schulte-Mattler WJ, Krack P: Treatment of chronic tension-type headache with botulinum toxin A: A randomized, double-blind, placebo-controlled multicenter study. Pain 109:110-114, 2004
- 53. Shafik A: Pudendal canal syndrome: A cause of chronic pelvic pain. Urology 60:199, 2002
- 54. Shafik A, el-Sherif M, Youssef A, Olfat ES: Surgical anatomy of the pudendal nerve and its clinical implications. Clin Anat 8:110-115, 1995
- 55. Shafik A, El-Sibai O: Botulin toxin in the treatment of nonrelaxing puborectalis syndrome. Dig Surg 15:347-351, 1998
- 56. Silberstein S: Botulinum neurotoxins: Origins and basic mechanisms of action. Pain Practice 4:S19-S26, 2004
- 57. Slocumb JC: Neurological factors in chronic pelvic pain: Trigger points and the abdominal pelvic pain syndrome. Am J Obstet Gynecol 149:536-543, 1984
- 58. Smith HS, Audette J, Royal MA: Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain 18:S147-S154, 2002
- 59. Sundaraj SR, Ponciano P, Johnstone C, Noore F, Castro M: Treatment of chronic refractory intractable headache with botulinum toxin type A: A retrospective study. Pain Practice 4:229-234, 2004
- 60. Swezey RL: Obturator internus bursitis: A common factor in low back pain. Orthopedics 16:783-785, 1993

CASE REPORT/Gajraj 337

61. Tarsy D, First ER: Painful cervical dystonia: Clinical features and response to treatment with botulinum toxin. Mov Disord 14:1043-1045, 1999

- 62. Tepper SJ: Treatment of headache pain with botulinum neurotoxins. Pain Practice 4:S38-S46, 2004
- 63. Tetzschner T, Sorensen M, Lose G, Christiansen J: Pudendal nerve function during pregnancy and after delivery. Int Urogynecol J Pelvic Floor Dysfunct 8:66-68, 1997
- 64. Thoumas D, Leroi AM, Mauillon J, Muller JM, Benozio M, Dennis P, Freger P: Pudendal neuralgia: CT-guided pudendal nerve block technique. Abdom Imaging 24:309-312, 1999
- 65. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB: Doubleblind study of botulinum toxin in spasmodic torticollis. Lancet 2:245-247, 1986
- 66. Turner ML, Marinoff SC: Pudendal neuralgia. Am J Obstet Gynecol 165:1233-1236, 1991
- 67. Welch MJ, Purkiss JR, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245-258, 2000
- 68. Wheeler AH, Goolkasian P, Gretz SS: Botulinum toxin A for the treatment of chronic neck pain. Pain 94:255-260, 2001